This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Buy Procter & Gamble (PG) After Q4 Earnings Report?
by Christopher Vargas
Procter & Gamble (PG) reported its fiscal 2019 Q4 earnings before the opening bell on Tuesday.
Procter & Gamble (PG) Stock Up on Q4 Earnings & Sales Beat
by Zacks Equity Research
Procter & Gamble (PG) posts robust fourth-quarter fiscal 2019 results. Also, the company provided upbeat guidance for fiscal 2020.
Economic and Earnings Date Deluge
by Zacks Equity Research
Economic and Earnings Date Deluge
Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More
by Mark Vickery
Another busy day awaits investors here in the middle of summer: U.S.-China trade talks resume, Personal Income & Spending data is out and Q2 earnings continue their torrent.
Procter & Gamble (PG) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
P&G (PG) delivered earnings and revenue surprises of 3.77% and 1.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Procter & Gamble (PG) Ahead of Earnings?
by Zacks Equity Research
Procter & Gamble (PG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Procter & Gamble (PG) is Poised to Beat on Q4 Earnings
by Zacks Equity Research
Procter & Gamble's (PG) fourth-quarter fiscal 2019 results are set to gain from ongoing productivity efforts, robust organic growth, higher shipment volume and favorable price/mix.
Should iShares Morningstar Large-Cap Value ETF (JKF) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for JKF
Should You Invest in the Fidelity MSCI Consumer Staples Index ETF (FSTA)?
by Zacks Equity Research
Sector ETF report for FSTA
Procter & Gamble (PG) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Procter & Gamble (PG) closed the most recent trading day at $113.85, moving -1.26% from the previous trading session.
Procter & Gamble (PG) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
P&G (PG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Check Out Colgate's (CL) Probability to Beat in Q2 Earnings
by Zacks Equity Research
Colgate's (CL) growth efforts indicate that it will likely retain the robust bottom-line surprise trend. However, soft margins and adverse currency may be deterrents.
Procter & Gamble (PG) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Procter & Gamble (PG) closed at $115.94, marking a +0.04% move from the previous day.
Is a Beat in Store for Boston Beer (SAM) in Q2 Earnings?
by Zacks Equity Research
Boston Beer (SAM) is likely to deliver robust second-quarter 2019 results on continued depletion and shipment growth. However, rising costs and a sluggish Samuel Adams brand may act spoilsport.
4 Stocks That Can Fuel More Record Growth in the Second Half of 2019
by Christopher Vargas
Investors have been keeping their eyes locked on the relationship between the US and China as the rhetoric spewing from the conflict has impacted the stock market for the over a year now.
Can Coca-Cola (KO) Retain Its Positive Earnings Streak in Q2?
by Zacks Equity Research
Coca-Cola's (KO) strategy of introducing new products with focus on expanding successful brands globally is aiding its performance. However, adverse currency may mar second-quarter 2019 results.
Colgate (CL) to Expand Skin Care Range With Filorga Buyout
by Zacks Equity Research
Colgate (CL) to expand the personal care portfolio with the acquisition of skin care business of France-based Filorga.
Procter & Gamble (PG) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Procter & Gamble (PG) closed the most recent trading day at $114.39, moving +0.56% from the previous trading session.
Colgate's (CL) Growth Efforts Well on Track Amid Soft Margins
by Zacks Equity Research
Colgate's (CL) strong surprise trend, higher pricing, strong innovation and expansion efforts bode well. However, high input costs and currency headwinds concerns.
Global Brands Bolster AB InBev's Sales, High Costs Remain Woe
by Zacks Equity Research
AB InBev (BUD) witnesses robust sales momentum on strength in global brands as well as global premiumization and revenue management plans. However, higher costs continue to mar the bottom line.
PepsiCo (PEP) Q2 Earnings Beat, Segmental Results Drive Sales
by Zacks Equity Research
PepsiCo (PEP) beats earnings and sales estimates in second-quarter 2019. Results gain from strength in all of its businesses.
Soap & Cleaning Materials Industry Outlook Upbeat on New Products
by Rajani Lohia
The FMCG space is likely to gain from investment in brands, innovation, cost-containment and pricing actions. However, its struggles against higher raw material and transportation costs continue.
3 Reasons Why Church & Dwight (CHD) Is a Hot Investment Pick
by Zacks Equity Research
Church & Dwight (CHD) is gaining on the back of strong organic sales trend, buyouts, focus on international business, product innovations and portfolio expansion.
Clorox (CLX) Stock Loses Sheen: What's Hindering its Growth?
by Zacks Equity Research
Clorox (CLX) expects gross margin to be flat in fiscal 2019 as gains from higher prices and cost-savings efforts are likely to be offset by higher costs and adverse currency rates.
Will Snacks Category Boost PepsiCo's (PEP) Earnings in Q2?
by Zacks Equity Research
PepsiCo (PEP) benefits from strength in snacking business and strong international presence. This should continue to aid top- and bottom-line growth in the second quarter.